Pharmacokinetic Effects of 4C9, An Anti-FcRn Antibody, in Rats: Implications for the Use of FcRn Inhibitors for the Treatment of Humoral Autoimmune and Alloimmune Conditions
- 1 April 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical Sciences
- Vol. 94 (4), 718-729
- https://doi.org/10.1002/jps.20297
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Pharmacokinetic/Pharmacodynamic Modeling of the Effects of Intravenous Immunoglobulin on the Disposition of Antiplatelet Antibodies in a Rat Model of Immune ThrombocytopeniaJournal of Pharmaceutical Sciences, 2003
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- High-Dose Intravenous Immune Globulin for Stiff-Person SyndromeNew England Journal of Medicine, 2001
- β2-microglobulin–deficient Mice Are Resistant to Bullous PemphigoidThe Journal of Experimental Medicine, 1997
- Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligandImmunity, 1994
- The SCID Mouse as a Model for AutoimmunityJournal of Autoimmunity, 1993
- Total lymphoid irradiation in alloimmunity and autoimmunityThe Journal of Pediatrics, 1987
- SUCCESSFUL RESPONSE TO INTRAVENOUS IMMUNOGLOBULIN IN AUTOIMMUNE HAEMOLYTIC ANAEMIABritish Journal of Haematology, 1985
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR MYASTHENIA GRAVISThe Lancet, 1984
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981